Yj. Wen et al., Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells, BLOOD, 97(6), 2001, pp. 1750-1755
Multiple myeloma (MM) is a B-cell malignancy. The monoclonal immunoglobulin
, secreted by myeloma plasma cells, carries unique antigenic determinants (
idiotype [Id]) that can be regarded as a tumor-specific antigen. Id-based i
mmunotherapy has been explored in myeloma patients for the purpose of enhan
cing or inducing Id-specific immune responses that might lead to tumor dest
ruction. However, despite some evidence obtained from mouse plasmacytoma mo
dels, it is still unclear whether Id-specific immunity may play a role in t
he regulation of tumor cells in MM, In the current study, using dendritic c
ells (DCs) as antigen-presenting cells, autologous Id-specific cytotoxic T
lymphocyte (CTL) lines containing both CD4(+) and CD8(+) T cells were gener
ated from myeloma patients. The results show that Id-specific CTLs not only
recognized and lysed autologous Id-pulsed DCs but also significantly kille
d the autologous primary myeloma cells, The cytotoxicity against the primar
y tumor cells was major histocompatibility complex (MHC) class I- and, to a
lesser extent, class Ii-restricted, indicating that myeloma cells could pr
ocess Id protein and present Id peptides in the context of their surface MH
C molecules, Furthermore, the CTLs lysed the target cells mainly through th
e perforin-mediated pathway because Concanamycin A, but not Brefeldin A-the
selective inhibitors for perforin- or Fas-mediated pathways-abrogated the
cytolytic activity of the cells, These CTLs secreted predominantly interfer
on-gamma and tumor necrosis factor-at on antigen stimulation, indicating th
at they belong to the type-1 T-cell subsets. Taken together, these findings
represent the first demonstration that Id-specific CTLs are able to lyse a
utologous tumor cells in MM and, thus, provide a rationale for Id-based imm
unotherapy in the disease. (Blood, 2001;97:1750-1755) (C) 2001 by The Ameri
can Society of Hematology.